Table 1.
Clinical characteristics of the patients
| Training cohort (n = 99) | Testing cohort (n = 42) | P value | |||
|---|---|---|---|---|---|
| STS | Non-STS | STS | Non-STS | ||
| Characteristic | (n = 28) | (n = 71) | (n = 12) | (n = 30) | 0.865 |
| Age, years | 56.7 ± 11.8 | 58.5 ± 13.1 | 0.121 | ||
| Gender | |||||
| Female (0) | 40 (40.4%) | 17 (40.5%) | 0.857 | ||
| Male (1) | 59 (59.6%) | 25 (59.4%) | |||
| KPS | 80 (60–100) | 80 (40–100) | 0.587 | ||
| WHO grade | |||||
| III | 32 (32.3%) | 16 (38.1%) | 0.640 | ||
| IV | 67 (67.7%) | 26 (61.9%) | |||
| MGMT | |||||
| Unmethyl. (0) | 47 (53.0%) | 20 (51.2%) | 0.988 | ||
| Methyl. (1) | 52 (47.0%) | 22 (48.8%) | |||
| TERTp | |||||
| Wildtype (0) | 21 (21.2%) | 10 (23.8%) | 0.516 | ||
| Mutation (1) | 78 (78.8%) | 32 (76.2%) | |||
Data are means ± standard deviations or numbers of patients with percentages in parentheses. P value was derived from the univariate association analyses between each clinical parameter. Calculated by using the Mann–Whitney U test for continuous variables and Pearson’s χ2 test for categoric variables. Gender, MGMT, TERTp with representative number of formula of risk probability in parentheses
STS short-term survivors, KPS Karnofsky Performance Score